Brief: Chromadex Shares Promising Findings From Clinical Study Showcasing ​​The Safety And Tolerability Of Nicotinamide Riboside (Nr) In Heart Failure With Reduced Ejection Fraction

Niagen Bioscience

04/10/2022 11:39

Oct 4 (Reuters) - Chromadex Corp  CDXC.O :
    * CHROMADEX SHARES PROMISING FINDINGS FROM CLINICAL STUDY
SHOWCASING ​​THE SAFETY AND TOLERABILITY OF NICOTINAMIDE
RIBOSIDE (NR) IN HEART FAILURE WITH REDUCED EJECTION FRACTION
    * CHROMADEX - STUDY MET PRIMARY ENDPOINT BY CONFIRMING THAT
NR WAS
SAFE AND WELL-TOLERATED IN PATIENTS WITH CLINICALLY STABLE HEART
FAILURE

Source text for Eikon:  ID:nBw5rlpcta 
Further company coverage:  CDXC.O 
 ((reuters.briefs@thomsonreuters.com;))